Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) Equity Average (2016 - 2025)

Seres Therapeutics' Equity Average history spans 11 years, with the latest figure at $38.3 million for Q3 2025.

  • For Q3 2025, Equity Average rose 221.36% year-over-year to $38.3 million; the TTM value through Sep 2025 reached $38.3 million, up 221.36%, while the annual FY2024 figure was -$15.5 million, 8.81% up from the prior year.
  • Equity Average for Q3 2025 was $38.3 million at Seres Therapeutics, down from $41.7 million in the prior quarter.
  • Across five years, Equity Average topped out at $159.2 million in Q1 2021 and bottomed at -$73.4 million in Q2 2024.
  • The 5-year median for Equity Average is $38.3 million (2025), against an average of $38.6 million.
  • The largest annual shift saw Equity Average surged 389.58% in 2021 before it plummeted 943.08% in 2024.
  • A 5-year view of Equity Average shows it stood at $153.6 million in 2021, then crashed by 74.49% to $39.2 million in 2022, then tumbled by 176.54% to -$30.0 million in 2023, then soared by 162.86% to $18.9 million in 2024, then soared by 103.29% to $38.3 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Equity Average are $38.3 million (Q3 2025), $41.7 million (Q2 2025), and $32.1 million (Q1 2025).